Evidence-gap map · non-drug interventions

Huntington Disease evidence gaps

39 registered non-drug trials, mapped by approach and outcome.

Which non-drug approaches have been tested for Huntington Disease, and which outcomes they were tested on. An empty cell means no matching trial was found among those searched: a possible gap, not proof that nobody has asked the question.

39registered non-drug trials
5with results posted
5recruiting as of 2026-11-16
30group × outcome cells with at least one trial
⚠️
Research information, not medical advice. These pages index what has been studied in registered trials. A trial existing, completing or posting results says nothing on its own about whether an approach works or is safe for you. Supplements and devices can interact with medicines. Discuss any change with your own clinician.

Evidence-gap matrix

Each number is the count of trials; "with results" is how many of them have posted results on ClinicalTrials.gov. A trial is counted once per group and per outcome domain it covers. The number in brackets after each group is its total trials for this condition.

none1–23–910–2930 or more
Registered non-drug trials for Huntington Disease by intervention group and primary outcome domain
Intervention groupFatigue and energyPost-exertional symptomsCognitionMood, anxiety and wellbeingPainSleepPhysical function and exercise capacityHeart rate, blood pressure and autonomicBreathing and lung functionQuality of lifeWeight and metabolic markersInflammation and other biomarkersSymptom severity and disease activityClinical events, survival and healthcare useFeasibility, adherence and safetyNot classified
Exercise and physical activity (9)··12··41 with results1·2··2·1·
Rehabilitation and therapy services (1)··1·········1···
Mind-body and psychological approaches (7)··12·····211 with results·11 with results·21
Cognitive training and education (1)··············1·
Diet, fasting and nutrition (1)··············1·
Sleep and circadian approaches (1)·····1········1·
Neuromodulation and electrical stimulation (5)··1···········31
Supplements and nutraceuticals (11)·····11····22·42 with results1
Other devices and digital tools (1)··1·········1···
Other behavioural, not yet classified (5)·········1····31 with results1

The table scrolls sideways: 16 outcome columns.

No trials found for this condition in: Breathing and respiratory training; Oxygen, light, temperature and manual therapies; Care delivery and health services.

Where the gaps are

Outcomes not found as a primary outcome in a group's trials

  • Among the 11 trials of supplements and nutraceuticals found, none used cognition as a primary outcome (4 trials of other approaches did).
  • Among the 11 trials of supplements and nutraceuticals found, none used mood, anxiety and wellbeing as a primary outcome (4 trials of other approaches did).
  • Among the 11 trials of supplements and nutraceuticals found, none used quality of life as a primary outcome (4 trials of other approaches did).

Questions studied but with no results posted

  • Neuromodulation and electrical stimulation × feasibility, adherence and safety: 3 trials registered, none with results posted (2 still recruiting)

Design a trial with DecenTrial (beta) Fund a component of this work

A gap here means no matching trial was found among those searched, not that an approach would work. About one trial in six has primary outcomes the rules cannot classify, so a few gaps may be measured under another name. Some gaps are gaps for good reason.

Most-studied approaches for Huntington Disease

Download this matrix (CSV) Non-drug evidence map Evidence brief RepurpOS condition page Condition page

How outcomes are grouped

Each trial's primary outcome measures are sorted into domains by keyword rules. 4 trials for this condition have primary outcomes the rules could not classify; they appear in the last column rather than being dropped. Checked against 90 hand-labelled outcomes; on a held-out sample of 30, the rules agreed with the hand label for 20 before adjustment, and every outcome they labelled was labelled correctly (misses were left unclassified).

Trial selection and exclusions follow the non-drug evidence map method. Source: ClinicalTrials.gov, searched 2026-11-16.